Nykredit A/S’s Vaxcyte PCVX Stock Holding History

Nykredit A/S’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$280K	Buy	+4,823	New	+$262K	﹤0.01%	901

Other funds holding PCVX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

PBPIA

Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Nykredit A/S's PCVX Position: Q2 2026 in Review

Nykredit A/S opened a new position in Vaxcyte (PCVX) in Q2 2026: 4,823 shares worth $280K. The stake represents ﹤0.01% of the portfolio and ranks #901 among its holdings.

222 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Nykredit A/S held 4,823 shares of Vaxcyte worth $280K as of Q2 2026.
Vaxcyte was a new Nykredit A/S position in Q2 2026.
Vaxcyte made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #901 holding.
222 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.